U. S. Food and Drug Administration has approved the blood-thinning drug Plavix to be available in generic versions in pharmacies, a report has revealed.
The application for the drug’s, with generic name clopidogrel, generic application was given by Pittsburgh-based Mylan Pharmaceuticals at first. According to the same, it will be the only one to sell the generic version in the market.
The drug is meant for those who either have a heart disease or have a family history of strokes and heart disease and want to avoid clotting problems and further risks.
It has been found that the drug was previously marketed by Sanofi-Aventis in collaboration with Bristol-Myers Squibb. A total of $6.7 billion for the last year has been made by its US sales, as per the findings.
The FDA has set different levels of dosage of the drug to be supplied by different pharmaceutical companies. It is being said that Dr. Reddy’s Laboratories, Gate Pharmaceuticals and Mylan along with Teva Pharmaceuticals would sell 300-milligram tablets of clopidogrel. And Aurobindo Pharma, Mylan, Roxane Laboratories, Teva and some others would sell the 75-milligram dosage.
- Postage Prices will Decrease from Sunday; USPS not too Happy About It
- Marriott and Starwood Hotels & Resorts Worldwide Inc Shareholders Approve to $14.41 Sales Deal
- UK plan to impose additional tax on sugary drinks
- Obesity during pregnancy may increase risk of very ‘large babies’
- Dropping Sales at Gap’s Key Brands hurt the Company’s Shares